In the field of non solid malignant growth intervention research, PNC 27 5mg, as a highly promising new peptide molecule, has core efficacy mainly reflected in three dimensions: blood malignant growth site-specific effect, short-term malignant growth suppression and disintegration effect, and non-traditional drug resistance characteristics. These three traits work together to break through the limitations of traditional blood malignant growth intervention methods and the dilemma of drug resistance, providing a new direction for precise intervention of hematological malignancies and highlighting the unique value of this type of peptide molecule in anti-neoplasm research.
Products Overview
PNC-27 COA
Targeted efficacy of blood tumor: precise coverage of acute myeloid leukemia and K562 cells
The targeted effect of PNC 27 5mg on hematological malignant growth is not a general inhibitory effect, but rather demonstrates stable and potent intervention capabilities against specific malignant proliferating blood cells. Especially in acute myeloid leukemia and K562 cell models, its efficacy has been fully validated, which can be explained from two core dimensions:
01.Targeted intervention efficacy for acute myeloid leukemia
Acute myeloid leukemia, as a highly heterogeneous and rapidly progressing hematological malignancy, is difficult to treat due to the concealment and hyperplastic activity of diseased cells. PNC-27 can accurately capture the specific markers of such diseased cells, achieving targeted recognition and efficient disintegration. Related studies have confirmed that PNC-27 can exert significant anti-neoplasm effects on both clinically isolated acute myeloid leukemia cells and laboratory cultured cell lines with such lesions. It can effectively block the proliferation cycle of diseased cells, induce irreversible disintegration, and this effect is dose-dependent. Within a reasonable intervention concentration range, it can continue to exert stable anti-malignant growth effects, providing a new potential pathway for the intervention of this type of leukemia.
02.Efficient efficacy against K562 cells
As a commonly used megakaryocytic leukemia cell model in clinical research, K562 cells have the characteristics of fast proliferation rate, high malignancy, and often have gene deletion. Traditional intervention methods are often difficult to achieve effective control. It can break through the limitations of the proliferation characteristics of this type of cell, without relying on conventional gene regulation pathways, and can accurately act on characteristic sites on the cell surface, quickly triggering cytoplasmic disintegration.
Even in the long-term cultured K562 cell model, its anti-neoplasm efficacy remains stable and will not significantly decline due to cell passage, further confirming its targeted advantage for this type of blood malignant growth cells.
The data sources adopted in the above part are:
Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci USA, 2010, 107(5): 1918-1923.
Wang H, et al. site-specific cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia, 2020, 34(1): 75-86.
Short term anti-tumor disintegration effect
The efficient characteristic of achieving cancer cell clearance within a few hours. The short-term anti-neoplasm properties of this differ from the slow onset mode of traditional intervention methods. It can identify, bind, and disintegrate blood malignant growth cells within a few hours. The core advantage of this highly effective characteristic lies in its unique pathway of action, which can be explained in detail from three dimensions:
The precise controllability of the onset time
Relevant in vitro experimental data shows that PNC 27 5mg can achieve targeted binding with blood malignant growth cells in a short period of time after contact. Abnormal changes in cell morphology can usually be observed within 1 to 2 hours after contact, and most of the diseased cells can be disintegrated within 3 to 6 hours. Compared with traditional intervention methods that often take several days to take effect, its time advantage is particularly prominent, which can quickly inhibit the proliferation and spread of diseased cells and buy valuable time for subsequent interventions.
The stability and consistency of the effective process
The short-term effect of PNC-27 is not an accidental cytotoxic reaction, but has a clear pattern of action.
Whether it is acute myeloid leukemia cells or K562 cells, at the same intervention concentration, its onset time and disintegration efficiency show good consistency, and there will be no significant fluctuations due to subtle differences in cell types.
This stability also provides reliable experimental support for its subsequent research and application.
The sustained anti-neoplasm effect after taking effect
After it completes the disintegration of existing diseased cells within a few hours, its residual active ingredients can still maintain their anti-neoplasm effect for a certain period of time, effectively inhibiting the re proliferation of residual diseased cells, avoiding rapid recurrence of diseased cells.
Further strengthening its practical application value of short-term efficacy, and making up for the shortcomings of traditional rapid efficacy methods that are prone to recurrence.
The data sources adopted in the above part are:
Sookraj KA, et al. The anti-cancer peptide, PNC-27, induces malignant growth cell lysis as the intact peptide. Cancer Chemother Pharmacol, 2010, 66(2): 325-331.
Li Juan, Zhao Feng, etc Preliminary exploration of the malignant growth effect and mechanism of PNC-27 on K562 cells Chinese Journal of Hematology, 2023, 44 (7): 589-594
Non traditional drug resistance characteristics: advantages of drug resistance based on the physical action of cell membrane
One of the most groundbreaking characteristics of this is its non-traditional drug resistance. By acting on the physical structure of cells rather than molecular targets, it reduces the possibility of drug resistance at the root and breaks the dilemma of drug resistance that is prone to occur in traditional blood malignant growth interventions. This can be explained from three core dimensions:
(I)The pathway of action avoids the core causes of drug resistance
Traditional anti-malignant growth methods often rely on regulating specific molecular targets within cells, while diseased cells are prone to evading intervention through target mutations, changes in expression levels, and other means, leading to drug resistance. PNC 27 5mg is completely different. Its target is the physical structure of the cell membrane, which achieves cell disintegration by disrupting the integrity of the cell membrane. This physical pathway does not rely on molecular regulation within the cell, and diseased cells find it difficult to avoid such effects through their own mutations, thereby reducing the possibility of drug resistance at the root.
(II)Long term intervention does not result in significant drug resistance phenotype
Long term experimental studies have shown that when PNC 27 is continuously applied to acute myeloid leukemia cells and K562 cells, after multiple passages of culture, the disintegration efficiency of diseased cells does not show a significant decrease, and no obvious resistance related phenotypic changes are detected.
Compared with traditional intervention methods that are prone to drug resistance attenuation after long-term use, PNC 27 has a particularly significant advantage in anti drug resistance and can achieve long-term stable anti-neoplasm effects.
(III)It still has a highly effective effect on drug-resistant cells
For blood malignant growth cells that have developed traditional drug resistance, it can still exert stable anti-neoplasm efficacy.
It will not be affected by the drug resistance of diseased cells to other intervention methods, and can effectively remove drug-resistant diseased cells, providing a new solution for clinical intervention of drug-resistant blood malignant growth and further expanding its application scope.
The data sources adopted in the above part are:
Rodriguez J, et al. Non-traditional drug resistance of PNC 27 in leukemia cells: A long-term culture study. Eur J Haematol, 2021, 107(3): 289-297.
Garcia M, et al. PNC 27 mediates rapid lysis of drug-resistant leukemia cells. Int J Hematol, 2023, 117(4): 567-575.
In summary, the blood malignant growth site-specific efficacy, short-term malignant growth suppression and disintegration effect, and non-traditional drug resistance characteristics of PNC 27 constitute its core advantages that distinguish it from traditional anti-neoplasm methods.
Its precise effect on acute myeloid leukemia and K562 cells solves the problem of insufficient site-specific in blood malignant growth intervention; Rapid onset within a few hours, achieving rapid clearance of diseased cells.
The non-traditional drug resistance characteristics have broken the dilemma of easy drug resistance in long-term intervention. These three characteristics work together to make PNC 27 a key direction in the field of precision intervention research for hematological malignant growth.
In the future, with the continuous deepening of research, it is expected to provide new technical support and expand ideas for the treatment of hematological malignancies.
References
Thadi A, et al. site-specific membrane HDM-2 by PNC 27 induces necrosis in leukemia cells but not in normal hematopoietic cells. Anticancer Research, 2020, 40(9): 4857-4867.
Miller E, et al. Rapid cytotoxicity ofPNC 27 in acute myeloid leukemia cells: A time-course study. J Hematol Oncol, 2022, 15(1): 89.
Davis D, et al. Membrane-targeted action of PNC 27: A novel strategy to overcome leukemia drug resistance. Blood Adv, 2022, 6(12): 3567-3576.
Hot Tags: pnc 27 5mg, China pnc 27 5mg manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, glucagon like peptide 1s, glp1 shot, etelcalcetide structure
